It’s Time Women’s Issues Are Not Left In The Dark
A New Bright Future For Women’s Health
It’s A World Problem.
Of all women are expected to experience a vaginal candida infection at least once in their lifetime.
Women worldwide will suffer from recurrent infections (over 4 episodes per year) by 2030.
But there is always a light
at the end of the Struggle.
Zero Candida Treatment Is
99.9999%
Successful
Overnight
In Candida Eradication
Introducing:
Zero Candida.
A non-drug blue light therapy in a SMART vaginal diagnostic device designed for the millions of women suffering from candidiasis.
Offering precise and personalized treatment, with individualized light frequency targeting, to produce
99.99% fungal eradication in only 3 hours.
Zero Candida is a novel diagnostic and therapeutic technology platform with a de novo regulatory pathway.
Designed to
Visualize. Diagnose. Treat.
Designed for
All vaginal conditions.
All stages of life.
Our Technology.
- No side effects
- No prescription
- At-home treatment
- Digital interaction & VoIP
Sensors & Features
Transparent gel matrix
For precise localized drug delivery, enhancing efficiency while minimizing discomfort.
Image sensor
Captures detailed visuals of the vaginal epithelium for more accurate diagnosis.
Temperature sensor
Tracks body temperature to assist in monitoring ovulation and overall health.
pH Sensor
Detects pH imbalances and signals when vaginal pH levels are restored.
Discreet and patient-centric design
Features a tampon-like shape for ease of insertion and maximum comfort.
Novel therapeutic antimicrobial blue light
Delivers 405 nm wavelength therapy that eliminates Candida by 99.99% in just 3 hours.
Bleeding sensor
Detects the presence of menstrual fluid with precision.
Wi-Fi chip
Enables voice-over-IP connectivity and HCP consultations.
Our Vision.
To reimagine vaginal health
We are designing a novel and personalized diagnostic and therapeutic vaginal technology to allow women to live life with zero limitations. To allow women to achieve their full potential by alleviating the stigma of hidden treatable diseases and vaginal disorders that lower quality of life and functioning, by placing women’s health back into their hands.
With Zero Candida, WE CAN.
Are you an angel?
Our Mission.
Make candida infections a thing of the past.
To provide an innovative & personalized home – based
diagnostic and novel therapeutic technology platform
for a range of vaginal conditions and disorders
to improve women’s vaginal health and wellbeing.
With Zero Candida, WE CAN.
Hybrid Mobile Healthcare.
Collect and transmit treatment data to the attending physician in real time, for assessment, treatment personalization and monitoring.
Seamless data transfer through Wi-fi chip and VoIP, allows for the convenience of remote care and telehealth consultation.
Connecting you
with your doctor.
Founders.
Eli Ben Haroosh
Co-Founder, Director & CEO
Serial entrepreneur in the field of women’s health, one of the leading start-ups owners in Israel, owns companies that are listed in the world, Past President of Vonetize until 2020. Vice President and CEO of Premier Dead Sea, Public Director of several companies and the president of Mariana Ltd, a medical cannabis R&D business
Dr.Asher Hozler
Co- Director
PhD of science, more than 30 years senior management experience primarily within the medical devices sector. Founded, taken public on Nasdaq, and COB of numerous companies (Urogen, Inspire MD, BioSig, and TheraCoat). Dr Holzer holds a PhD in nuclear physics from the Hebrew University of Jerusalem.
Our Team.
Dr. Irene Zaiton, PhD, MBA | VP of Operations & Research
Two decades of management experience in biotech and pharma. Previously held positions Mindset BioPharmaceuticals and MindGenix; R&D manager at Esther Neurosciences; Research PM at Israel’s National Tissue Bank; Head of research Ramot Company (TAU) Marketing and Bizdev manager Target Tech incubator, Operations manager at Thiriga Pharmaceuticals.
Tammy Dvir Bar-On | VP Product & Marketing
15 years experience in marketing and product management. A seasoned expert in medical equipment and aesthetics. Specific and specialized expertise in product process development, market-specific client needs analysis, and delivering successful product launches. Led the Professional Products department at Lumenis Beauty until recently.
Yosh Dolberg | Senior VP Development & Engineering
Extensive industry experience: Traquat Urogen Pharma, VP AOI Orbotek (Computer Vision), Head of Medical systems Direx (shock waves, MRI, γ radiation), VP Dev Keulik & Sofa (SEMI industry), Cubital (3D printing). >10 patents and co-author on many peer-reviewed articles. B.Sc. Elec Engineering (Technion) M.Sc. Comp Engineering (BIU).
Dr. Zeev Schmelzer | Patent Advisor
Dr. Zeev Schmelzer (PhD) Graduated with a doctorate in patents.
Patent Advisor Patent attorney in the field of mechanics, medical equipment, biology and medicine, with over 13 years of experience in the field.
Advisory Board.
Prof. Ehud Davidson | Chairman of advisory clinical Board
CEO of the largest health maintenance organization (HMO) in the State of Israel, Clalit (52% of the market share). Led the treatment of the majority of Israeli patients, in the community, and Clalit hospital setting. Prof Davidson also led and implemented the highly successful Covid-19 vaccination project in Israel.
Prof. Asnat Walfisch | Member of the Clinical Board
MD (honors BGU) Gynecology (Soroka & Sheba MCs). Maternal and Fetal Medicine specialization (University of Toronto, Canada). Past director of the OBGYN department at Hadassah Mount Scopus. Current Head of Helen Schneider Women’s Hospital (Rabin MC). Has published~ 150 scientific articles in gynecology and maternal & fetal medicine.
Prof. Tal Biron | Member of the clinical Board
Head of Women’s Health and Maternity Department (Meir Medical Center of Clalit). Chairperson of the Israeli Society for Maternal & Fetal Medicine. Full Clinical Professor at TAU. Specialized in gynecology (Meir MC) with M.D from The Technion. Maternal & Fetal Medicine specialization at Washington University, Missouri, USA.
Dr Susan Alpert, Ph.D., M.D. | Member of the clinical Board
Past VP Regulatory Science Affairs (C. R. Bard). Several management positions US Food and Drug Administration (FDA). Head of SFA Regulatory, LLC- specializing in strategies for introducing medical devices/products to the global market. Past VP Global Regulation (Medtronic), Microbiologist and pediatrician, specialist in infectious diseases.
What Experts Think.
_
Explore The Evidence.
Will I have to live with this condition forever?
“Instead of trying to self-medicate it is much more productive to get an appointment with the doctor. I am wondering if I am cured for life or if I will need long term treatment.”
It affects my sexual intimacy
“I had to withdraw from intimate encounters because the fungal infection came like a letter in the mail the very next day after intercourse.”
It makes me depressed and anxious
“It doesn’t really matter what I do. Nothing seems to work so why should I even get dressed to go anywhere? I don’t feel like it . It ’s just to bite the bullet . If you haven’t had a yeast infection…you don’t know what you are missing.”
Will I have to live with this condition forever?
“Instead of trying to self-medicate it is much more productive to get an appointment with the doctor. I am wondering if I am cured for life or if I will need long term treatment.”
It affects my sexual intimacy
“I had to withdraw from intimate encounters because the fungal infection came like a letter in the mail the very next day after intercourse.”
It makes me depressed and anxious
“It doesn’t really matter what I do. Nothing seems to work so why should I even get dressed to go anywhere? I don’t feel like it . It ’s just to bite the bullet . If you haven’t had a yeast infection…you don’t know what you are missing.”
Treatments are ineffective
“Vaginal gels do not meet the required standards and can cause a recurrence of the infection by irritating the vagina…and it causes me to get involved again.” 35 yrs with a history of three VVC cases in 5 years).
My work is affected
“My work conditions are very stressful and these tensions and work stress cause my infection to constantly recur and the treatment to be ineffective for me”. 38 yrs with a 1-year history of
RVVC.
Maybe its genetic
“I do not like to see a doctor because my mother, despite being 50 years old, still suffers from this infection and medical treatments have not been effective. I believe that genetics is very influential, and I think my genes are the same as my mother’s, so treatment is useless.” 42 yrs with 18 years of RVVC history
Latest News.
- Zero Candida
Zero Candida Receives South African Patent for its ZC- 01 device
VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZC”) (TSXV: ZCT), an Israeli FemTech medical device start-up, is pleased to announce…
- Zero Candida
Zero Candida Announces Full Transaction and Being Trading November 25th on the TSX Venture Exchange (Canada)
VANCOUVER, BC, Nov. 25, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZCT”), (TSXV: ZCT) an Israeli FemTech medical device start-up, is pleased to announce…
- Zero Candida
Zero Candida Announces TSX Venture Exchange Listing Date
Zero Candida (formerly 1319743 B.C. Ltd.), has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company (“ZC” and “Acquisition” respectively). In…
- Zero Candida
Zero Candida Receives South African Patent for its ZC- 01 device
VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZC”) (TSXV: ZCT), an Israeli FemTech medical device start-up, is pleased to announce…
- Zero Candida
Zero Candida Announces Full Transaction and Being Trading November 25th on the TSX Venture Exchange (Canada)
VANCOUVER, BC, Nov. 25, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZCT”), (TSXV: ZCT) an Israeli FemTech medical device start-up, is pleased to announce…
- Zero Candida
Zero Candida Announces TSX Venture Exchange Listing Date
Zero Candida (formerly 1319743 B.C. Ltd.), has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company (“ZC” and “Acquisition” respectively). In…
- Zero Candida
Zero Candida Applies to List its Shares on the TSX Venture Exchange
VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ — Zero Candida Technologies Inc. (the “Company” or “Zero Candida”) (TSXV: ZCT), a technology company focused on development and…
- Zero Candida
Zero Candida Announces First Intellectual Property in South Africa
Company is in the process to be listed on the TSX Venture Exchange (Canada) at a Proposed Valuation of 40 million Canadian Dollars TEL AVIV,…
- Zero Candida
Zero Candida Announces its Intent to Complete Listing of its Shares on the TSX Venture Exchange (Canada) at a Proposed Valuation of 40 million Canadian Dollars
TEL AVIV, Israel, June 3, 2024 /CNW/ — Zero Candida (the “Company” or “ZC “) an Israeli FemTech medical device start-up is pleased to announce…
- Zero Candida
Zero Candida Technologies, Inc. $ZCT Going public on the TSXV Monday November 25th 2024
VANCOUVER, BC, Nov. 18, 2024 /CNW/ — Zero Candida Technologies Inc. (the “Company” or “Zero Candida”) (TSXV: ZCT), a technology company focused on development and…
